MENUMENU
  • Covid Clear
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • News, Media & Events

        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • Media Coverage
        • Company News
        • Media Press Kit
        • Videos
        • Events
  • About Us

        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Imutex Ltd.
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • img

          LATEST PRESS RELEASE

          11.06.20 Major New Contract Signed

        • UPCOMING EVENTS

          Mello Event – presenting only11 Jul, Online
  • Volunteers
  • Careers
  • Contact Us

Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim – WSJ.com

August 5, 2014 11:28 am

https://online.wsj.com/article/PR-CO-20140804-901143.html

Follow @hVIVO_UK

Comments are closed here.

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2020 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy